Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Post by RazeKreationson May 25, 2021 2:17pm
161 Views
Post# 33260969

Potential

PotentialAnother reason for having optimism for growth in VTM is the fact that before the pandemic began is that labs and institutions were having problems getting VTM that was reliable as far as quality is concerned. Poor packaging that contributed to contamination and product or had short shelf life or was not up to quality standards when packaged because of poorly trained staff and facility conditions of manufacturers that was not adequate to avoid contamination. Because of those problems many took on the role of producing their own VTM.  This has a cost for those that do, in time and resources and typically made in small batches because of short shelf life. MBX is determined to manufacture in large enough volumes that they will be able to produce VTM at a very cost-effective finished product cost, making it more likely for institutions and labs to buy from MBX.
MBX has gone from a little-known supplier of Qaps and Antigens because of white labeled products to a very well-respected supplier of branded products, with a growing distribution network and many recognizing the quality of those products. VTM is not a new product for MBX. They have been making it for many years for their own use.  They perfected it for longer shelf life and now they have made it available to others starting with Ontario.
2019 Imports of VTM was 55 million dollars alone never mind the value of internally made product.
Potential to gain customers that have produced their own from efficiencies gained in large volume production.


<< Previous
Bullboard Posts
Next >>